Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

NCT03580928 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG: Venetoclax
DRUG: Obinutuzumab
DRUG: Acalabrutinib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]